Having trouble accessing articles? Reset your cache.

ICER’s DMD recommendations include changes to outcome measures, pricing

After finding that all three DMD therapies it reviewed lack clinical data to support a high price, ICER recommended that manufacturers and payers implement pricing policies better aligned with their value and suggested trial endpoints that

Read the full 367 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE